# Syndax Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syndax-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.syndax.com/
- Total disclosed funding: $142M
- Latest round: Series C (Aug 24, 2015)
- Investors on record: 17

## About

Syndax Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing innovative therapies for oncology, addressing critical unmet medical needs in cancer treatment.Founded in 2005 and headquartered in New York, US, Syndax Pharmaceuticals specializes in oncology drug development. The company has engaged in multiple funding rounds, including a Private Placement/Follow on raising USD 125.00 mn, totaling USD 125.00 mn in capital raised. Syndax has completed 14 deals, with its most recent deal occurring on March 2, 2016.Syndax Pharmaceuticals specializes in developing innovative oncology therapies aimed at treating significant unmet medical needs, particularly in acute leukemia and chronic graft-versus-host disease. The company's core product offerings include revumenib and axatilimab, both of which were approved in the U.S. in 2024. Revumenib is being investigated for its effectiveness in genetically defined acute leukemias, such as those with an NPM1 mutation, while axatilimab is being explored in earlier lines of therapy and potential indications like idiopathic pulmonary fibrosis. These therapies are designed to provide meaningful clinical results, enhancing patient outcomes in challenging cancer diagnoses. Syndax’s products are primarily marketed in the United States, with ongoing clinical trials assessing their broader applicability in other geographical markets.Syndax Pharmaceuticals generated revenue of USD 139.71 mn in 2021. The company’s business model includes direct sales to healthcare providers and hospitals, which serve as primary customers for these specialized treatments. The pricing structure for these therapies is determined based on their innovative nature and clinical effectiveness. Revenue transactions typically occur through negotiated contracts with healthcare institutions and payers, ensuring access to their therapies for patients in need. The company further enhances its revenue potential by engaging in clinical trials and research partnerships to support the ongoing development of its product pipeline.Syndax Pharmaceuticals plans to leverage recent funding to advance the development of its oncology therapies, including revumenib and axatilimab. These products are expected to expand into new markets, particularly focusing on international healthcare systems as the company establishes its presence by 2025. The funds from the latest funding rounds will be allocated to enhance clinical trial capabilities and explore additional oncology indications, ensuring the company remains at the forefront of innovation in cancer treatment.

## Funding rounds

- Series C, Aug 24, 2015, $80M — Domain Associates, Forward Ventures, OrbiMed Advisors, Fidelity Investments, Arrowpoint Ventures, Tavistock Group, Jennison Associates, EcoR1 Capital, Cormorant Asset Management, RMI Partners, BioMed Ventures, MRM Capital, Delos Capital Partners
- Series B, Aug 27, 2013, $27M — Domain Associates, Forward Ventures, MPM BioImpact, RMI Partners
- Series A, Aug 3, 2010, $6M — Domain Associates, Forward Ventures, Avalon Ventures, Pappas Capital, MC Life Science Ventures, MPM BioImpact
- Series A, Jan 22, 2010, $9M — Domain Associates, Forward Ventures, Avalon Ventures, Pappas Capital, MPM BioImpact
- Series A, Apr 3, 2007, $20M — Domain Associates, Forward Ventures, Avalon Ventures, Pappas Capital, MPM BioImpact

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B, Series C
- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A, Series B, Series C
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- MC Life Science Ventures — Series A
- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Arrowpoint Ventures (https://capitalatlas.ai/funds/arrowpoint-ventures) — Series C
- Tavistock Group (https://capitalatlas.ai/funds/tavistock-group) — Series C
- Jennison Associates — Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- BioMed Ventures — Series C
- MRM Capital — Series C
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series C